The NASDAQ-listed biotechnology company OpGen, Inc. based in Gaithersburg, Maryland, USA, and Curetis GmbH domiciled in Holzgerlingen, Germany, having subsidiaries in Austria and the US, will combine their business. The contemplated combination would create a transatlantic listed company with an innovative commercial-stage molecular diagnostics and bioinformatics franchise focusing on infectious diseases and antibiotic resistance.
Through an acquisition vehicle, OpGen has purchased all shares in Curetis GmbH from Curetis N.V., the Dutch Euronext-listed parent company. The consideration consists of newly issued ordinary shares in OpGen, ultimately to be held by the current shareholders of Curetis N.V. The planned “share exchange” is, inter alia, still subject to the approval of the parties’ respective shareholders. Closing is expected at the beginning of 2020.
Legal and Tax (Germany): LPA-GGV Frankfurt: Matthias Krämer (Tax, Lead), Ina von Raven (Corporate/M&A, Co-Lead), Dr. Jens Jensen (Employment), Dr. Eberhard Koch (Contracts, IP), Patrick Bullinger (Tax), Dr. Mareen Poser (Regulatory), Peter Stainer (Contracts)
Dutch Law: Weidema van Tol (Badhoevedorp), Sorina van Kommer
US Law / Lead Counsel: Ballard Spahr LLP (Philadelphia), Mary J. Mullany
Hamburger Allee 2-4
60486 Frankfurt am Main
+49 69 97961-171